We are live on ! Find out more
FCMV

Foresite Capital Management V Portfolio holdings

AUM $271M
1-Year Est. Return 309.87%
This Fund
S&P 500
This Quarter Est. Return
+9.48%
1 Year Est. Return
+309.87%
3 Year Est. Return
+356.88%
5 Year Est. Return
+250.56%
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$67.6M
Cap. Flow
+$94.2M
Cap. Flow %
29.26%
Top 10 Hldgs %
89.88%
Holding
20
New
3
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$60.1M
2
IVVD icon
Invivyd
IVVD
+$47.5M
3
HLTH
Cue Health Inc. Common Stock
HLTH
+$18.4M

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$14.6M
2
ALXO icon
ALX Oncology
ALXO
+$12.6M
3
TNGX icon
Tango Therapeutics
TNGX
+$4.55M

Sector Composition

Rank Sector Weight
1 Healthcare 96.73%
2 Financials 1.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGC
1
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$66M 20.51%
+5,326,472
New +$60.1M
CGEM icon
2
Cullinan Oncology
CGEM
$1.05B
$61.6M 19.16%
2,731,410
– –
IVVD icon
3
Invivyd
IVVD
$180M
$54.1M 16.81%
+1,280,640
New +$47.5M
ACRS icon
4
Aclaris Therapeutics
ACRS
$730M
$22.6M 7.04%
1,258,243
– –
KNTE
5
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$20.1M 6.26%
875,001
– –
QSI icon
6
Quantum-Si Incorporated
QSI
$168M
$19.5M 6.07%
2,342,061
– –
HLTH
7
DELISTED
Cue Health Inc. Common Stock
HLTH
$13.8M 4.29%
+1,167,782
New +$18.4M
NRIX icon
8
Nurix Therapeutics
NRIX
$2.43B
$13.5M 4.2%
451,522
– –
IRON icon
9
Disc Medicine
IRON
$2.83B
$9.84M 3.06%
81,171
– –
HIMS icon
10
Hims & Hers Health
HIMS
$6.5B
$7.97M 2.48%
1,056,922
– –
PHVS icon
11
Pharvaris
PHVS
$2.39B
$6.46M 2.01%
364,142
– –
ME
12
DELISTED
23andMe Holding Co
ME
$6.34M 1.97%
35,000
– –
PRDS
13
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$6M 1.86%
602,500
– –
PHICU
14
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
$5.6M 1.74%
960,000
– –
RACB
15
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.92M 1.53%
500,000
– –
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.59B
$2.49M 0.77%
250,000
– –
LHDX
17
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$760K 0.24%
485,000
– –
ALXO icon
18
ALX Oncology
ALXO
$273M
– –
-231,200
Closed -$12.6M
RLAY icon
19
Relay Therapeutics
RLAY
$4.02B
– –
-400,000
Closed -$14.6M
TNGX icon
20
Tango Therapeutics
TNGX
$4.34B
– –
-400,000
Closed -$4.55M

Similar funds

MAM
Mullooly Asset Management Wall Township, New Jersey $271M AUM 16.93% 1-Year Est. Return
MLM
Mount Lucas Management Newtown, Pennsylvania $271M AUM 25.49% 1-Year Est. Return
PFG
Prosperity Financial Group San Ramon, California $271M AUM 30.27% 1-Year Est. Return
MCM
Moerus Capital Management New York $271M AUM 58.78% 1-Year Est. Return
RP
Ravenswood Partners Mclean, Virginia $271M AUM
PCM
Punch Card Management Winter Park, Florida $271M AUM 11.49% 1-Year Est. Return
ACH
Axis Capital Holdings Pembroke, Bermuda $270M AUM 16.26% 1-Year Est. Return
S
Siemens Munich, Germany $272M AUM 183.71% 1-Year Est. Return

Foresite Capital Management V's Q3 2021 Portfolio in Review

As of Q3 2021, Foresite Capital Management V held 20 positions worth $322M, up 27% from $254M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Foresite Capital Management V deployed $94.2M of net new capital in Q3 2021, opening 3 new positions. Its largest new stake was SomaLogic, Inc. Class A Common Stock: 5,326,472 shares worth $66M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Financials.

On the sell side, the most notable exit was Relay Therapeutics, an estimated $14.6M sold.

  • Foresite Capital Management V's largest Q3 2021 buy was SomaLogic, Inc. Class A Common Stock: 5,326,472 shares worth $66M.
  • Foresite Capital Management V fully exited Relay Therapeutics in Q3 2021, selling an estimated $14.6M.
  • Foresite Capital Management V's ten largest holdings make up 90% of its $322M portfolio in Q3 2021.
  • Foresite Capital Management V opened 3 new positions and closed 3 in Q3 2021.
  • Foresite Capital Management V's portfolio value rose 27% quarter-over-quarter to $322M.

Based on Foresite Capital Management V's 13F filing for Q3 2021, filed 12 Nov 2021.